Narrowband (NB) UV-B is known as an effective and safe treatment for atopic dermatitis (AD). However, there is a lack of studies regarding prognostic factors for favorable response and its duration.
Objective
The aim of the study was to evaluate the efficacy of NB-UV-B for AD, in a large cohort and “real-life” setting.
Methods
This is a retrospective cohort study based on the medical records of patients with moderate to severe AD treated with NB-UV-B therapy between 2000 and 2017 with a long-term follow-up (≥3 years) after completing therapy.
Results
A total of 390 of 555 AD patients who were scheduled for NB-UV-B were included; among them, 55.4% responded well to treatment. Facial involvement, presence of adverse effects, lower number of treatments, and pretreatment immunoglobulin E levels greater than 4000 were related to poorer response. There was an overall median response duration of 12 months with a greater relapse rate among the patients younger than 18 years.
Conclusions
Narrowband UV-B phototherapy shows high and long-lasting efficacy in AD. Patients with facial involvement and patients with high immunoglobulin E levels respond less to treatment. Response duration seems to be shorter for patients younger than 18 years.
Get full access to this article
View all access options for this article.
References
1.
MargolisJS, AbuabaraK, BilkerW, et al.Persistence of mild to moderate atopic dermatitis. JAMA Dermatol, 2014; 150:593–600.
2.
Guttman-YasskyE, LowesMA, Fuentes-DuculanJ, et al.Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol, 2007; 119:1210–1217.
3.
EliasPM, HatanoY, WilliamsML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol, 2008; 121:1337–1343.
4.
BoguniewiczM, SampsonH, LeungSB, et al.Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis. J Allergy Clin Immunol, 2001; 108:651–652.
5.
Bath-HextallFJ, BirnieAJ, RavenscroftJC, et al.Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol, 2010; 163:12–26.
6.
EwingCI, AshcroftC, GibbsAC, et al.Flucloxacillin in the treatment of atopic dermatitis. Br J Dermatol, 1998; 138:1022–1029.
7.
WeinbergE, FourieB, AllmannB, et al.The use of cefadroxil in superinfected atopic dermatitis. Curr Ther Res, 1992; 52:671–676.
8.
WahlgrenCF, HägermarkO, BergströmR. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol, 1990; 122:545–551.
9.
KleinPA, ClarkRA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol, 1999; 135:1522–1525.
10.
HermanSM, VenderRB. Antihistamines in the treatment of dermatitis. J Cutan Med Surg, 2003; 7:467–473.
11.
van ZuurenEJ, ApfelbacherCJ, FedorowiczZ, et al.No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. Syst Rev, 2014; 3:25.
12.
PatriziA, RaoneB, RavaioliGM. Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol, 2015; 8:511–520.
13.
LarköO, SwanbeckG. Is UVB treatment of psoriasis safe? A study of extensively UVB-treated psoriasis patients compared with a matched control group. Acta Derm Venereol, 1982; 62:507–512.
14.
WeischerM, BlumA, EberhardF, et al.No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol, 2004; 84:370–374.
15.
BraddockM, HananiaNA, SharafkhanehA, et al.Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf, 2018; 41:489–509.
16.
GambichlerT. Management of atopic dermatitis using photo(chemo)therapy. Arch Dermatol Res, 2009; 301:197–203.
17.
MajoieIM, OldhoffJM, van WeeldenH, et al.Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol, 2009; 60:77–84.
18.
JeklerJ, LarköO. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study. J Am Acad Dermatol, 1990; 22:49–53.
19.
HjerppeM, HasanT, SaksalaI, et al.Narrow-band UVB treatment in atopic dermatitis. Acta Derm Venereol, 2001; 81:439–440.
20.
HanifinJM, RajkaG. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh), 1980; 92:44–47.
21.
SimpsonE, BissonnetteR, EichenfieldLF, et al.The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol, 2020; 83:839–846.
22.
SidburyR, DavisDM, CohenDE, et al.Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol, 2014; 71:327–349.
23.
KruegerJG, WolfeJT, NabeyaRT, et al.Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med, 1995; 182:2057–2068.
24.
OzawaM, FerencziK, KikuchiT, et al.312-Nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med, 1999; 189:711–718.
25.
FaergemannJ, LarköO. The effect of UV-light on human skin microorganisms. Acta Derm Venereol, 1987; 67:69–72.
26.
RingJ, AlomarA, BieberT, et al.Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol, 2012; 26:1176–1193.
27.
LarköO. Phototherapy of eczema. Photodermatol Photoimmunol Photomed, 1996; 12:91–94.
28.
KrutmannJ. Phototherapy for atopic dermatitis. Clin Exp Dermatol, 2000; 25:552–558.
29.
CollinsP, FergusonJ. Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. Br J Dermatol, 1995; 133:653–655.
30.
Hudson-PeacockMJ, DiffeyBL, FarrPM. Narrow-band UVB phototherapy for severe atopic dermatitis. Br J Dermatol, 1996; 135:332.
31.
Grundmann-KollmannM, BehrensS, PoddaM, et al.Phototherapy for atopic eczema with narrow-band UVB. J Am Acad Dermatol, 1999; 40:995–997.
32.
Der-PetrossianM, SeeberA, HönigsmannH, et al.Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol, 2000; 142:39–43.
33.
BerneburgM, RöckenM, BenedixF. Phototherapy with narrowband vs broadband UVB. Acta Derm Venereol, 2005; 85:98–108.
34.
ReynoldsNJ, FranklinV, GrayJC, et al.Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet, 2001; 357:2012–2016.
35.
Fernández-GuarinoM, Aboin-GonzalezS, BarchinoL, et al.Treatment of moderate and severe adult chronic atopic dermatitis with narrow-band UVB and the combination of narrow-band UVB/UVA phototherapy. Dermatol Ther, 2016; 29:19–23.
36.
ClowryJ, MolloyK, NestorL, et al.Narrow-band ultraviolet B phototherapy outcomes in atopic dermatitis—a single-centre retrospective review. Photodermatol Photoimmunol Photomed, 2018; 34:217–219.
37.
ClaytonTH, ClarkSM, TurnerD, et al.The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol, 2007; 32:28–33.
38.
TanE, LimD, RademakerM. Narrowband UVB phototherapy in children: a New Zealand experience. Australas J Dermatol, 2010; 51:268–273.
39.
PavlovskyM, BaumS, ShpiroD, et al.Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis?J Eur Acad Dermatol Venereol 2011;25:727–729.
40.
MokZR, KohMJ, ChongWS. Is phototherapy useful in the treatment of atopic dermatitis in Asian children? A 5-year report from Singapore. Pediatr Dermatol, 2014; 31:698–702.
41.
SeccombeE, WynneMD, ClancyC, et al.A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit. Photodermatol Photoimmunol Photomed, 2020; 37:34–38.
42.
EustaceK, DolmanS, AlsharqiA, et al.Use of phototherapy in children. Pediatr Dermatol, 2017; 34:150–155.
43.
DayalS, PathakK, SahuP, et al.Narrowband UV-B phototherapy in childhood atopic dermatitis: efficacy and safety. An Bras Dermatol, 2017; 92:801–806.
44.
Magdaleno-TapialJ, Ortiz-SalvadorJM, Valenzuela-OñateC, et al.Comparison of phototherapy in pediatric and adult patients. Actas Dermosifiliogr, 2020; 111:41–46.
45.
BurrowsD, PenmanRW. Prognosis of the eczema-asthma syndrome. Br Med J, 1960; 2:825–828.
46.
SandströmMH, FaergemannJ. Prognosis and prognostic factors in adult patients with atopic dermatitis: a long-term follow-up questionnaire study. Br J Dermatol, 2004; 150:103–110.
RystedtI. Long term follow-up in atopic dermatitis. Acta Derm Venereol Suppl (Stockh), 1985; 114:117–120.
49.
LammintaustaK, KalimoK, RaitalaR, et al.Prognosis of atopic dermatitis. A prospective study in early adulthood. Int J Dermatol, 1991; 30:563–568.
50.
KiefferM, BergbrantIM, FaergemannJ, et al.Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrheic dermatitis. J Am Acad Dermatol, 1990; 22:739–742.
51.
FaergemannJ. Pityrosporum species as a cause of allergy and infection. Allergy, 1999; 54:413–419.
52.
SaltBH, BoguniewiczM, LeungDY. Severe refractory atopic dermatitis in adults is highly atopic. J Allergy Clin Immunol, 2007; 119:508–509.
53.
KatohN, HiranoS, KishimotoS. Prognostic factor of adult patients with atopic dermatitis. J Dermatol, 2008; 35:477–483.
54.
KiiskiV, KarlssonO, RemitzA, et al.High serum total IgE predicts poor long-term outcome in atopic dermatitis. Acta Derm Venereol, 2015; 95:943–947.
55.
OlesenCM, HolmJG, NørresletLB, et al.Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol, 2019; 33:1562–1568.
56.
FerrucciS, CasazzaG, AngileriL, et al.Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med, 2020; 9.
